论文部分内容阅读
目的:探讨DC-CIK细胞联合化疗对卵巢癌患者外周血CK19-mRNA表达的影响。方法:将37例外周血CK19表达阳性的中晚期卵巢癌患者随机分为两组,实验组25例采用PC方案+DC-CIK进行治疗,对照组12例采用PC方案进行治疗,采用相对定量逆转录聚合酶链式反应(RT-PCR)检测治疗前及3个周期后两组患者CK19-mRNA表达的水平,并观察患者的疗效及生存期。结果:经3个周期治疗后,实验组、对照组CK19-mRNA相对表达量均下降,差异有统计学意义(P<0.05);与对照组相比,实验组下降更明显(P<0.05)。实验组有效率(72.0%)明显高于对照组(33.3%)(P<0.05),中位生存期(11个月)明显长于对照组(7个月)(χ2=4.36,P=0.032 8)。两组Ⅲ+Ⅳ度白细胞减少率的比较差异有统计学意义(P<0.05),其余Ⅲ+Ⅳ度毒副反应发生率差异无统计学意义(P>0.05)。结论:DC-CIK细胞可有效清除卵巢癌患者的微残留灶,使外周血CK19-mRNA表达量下降,起到化疗增效的作用。
Objective: To investigate the effect of DC-CIK combined with chemotherapy on the expression of CK19-mRNA in peripheral blood of ovarian cancer patients. Methods: Thirty-seven patients with moderate and advanced ovarian cancer with positive expression of CK19 in peripheral blood were randomly divided into two groups. In the experimental group, 25 cases were treated with PC program and DC-CIK. In the control group, 12 cases were treated with PC program. Relative quantitative reversal The levels of CK19-mRNA in both groups before and after 3 cycles were detected by polymerase chain reaction (RT-PCR). The efficacy and survival of the patients were observed. Results: After 3 cycles of treatment, the relative expression of CK19 mRNA in the experimental group and the control group decreased significantly (P <0.05), compared with the control group, the experimental group decreased more significantly (P <0.05) . The effective rate (72.0%) in the experimental group was significantly higher than that in the control group (33.3%) (P <0.05), and the median survival time (11 months) was significantly longer than that in the control group (7 months) ). There were significant differences in the leukopenia rates of grade Ⅲ + Ⅳ between the two groups (P <0.05), but there was no significant difference in the incidence of grade Ⅲ + Ⅳ toxicity between the two groups (P0.05). Conclusion: DC-CIK cells can effectively remove the micro-residual tumor in patients with ovarian cancer, so that the expression of CK19-mRNA in peripheral blood decreased, which can play a role of chemotherapy synergies.